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and their skill level, and a possible tendency to 
be selected on a team to allow a more flexible 
strategy.4 We speculate that players who throw 
right-handed and bat left-handed enjoy an addi-
tional biomechanical advantage, with the domi-
nant (throwing) hand being placed further from 
the hitting end of the bat, providing a longer 
lever with which to hit the ball (potentially at 
the expense of bat control5). Given these sport-
specific explanations, our findings argue against 
any advantage due to hemispheric lateralization.
David L. Mann, Ph.D.
Vrije Universiteit Amsterdam 
Amsterdam, the Netherlands
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Dabigatran Reversal with Idarucizumab
To the Editor: Data provided by Pollack and 
colleagues (Aug. 3 issue)1 suggest a dissociation 
between the normalization of the coagulation 
profile and the establishment of effective hemo-
stasis after the administration of idarucizumab 
in patients with uncontrolled bleeding. The median 
time to the cessation of bleeding was 2.5 hours 
among patients with nonintracranial hemorrhage. 
In analyses reported separately, the median time to 
the cessation of bleeding was 3.5 hours among pa-
tients with gastrointestinal bleeding and 4.5 hours 
among those with nonintracranial and nongastro-
intestinal bleeding.2 The median time to the ces-
sation of bleeding was 11.4 hours when intracra-
nial hemorrhage was included in the analysis 
involving patients with serious bleeding.3 Should 
clinicians rely solely on idarucizumab and hope 
that their patients do not die from uncontrolled 
hemorrhage while waiting for hemostasis to be 
established? A reasonable approach would be to 
administer blood-component therapy (e.g., pro-
thrombin complex concentrate and activated pro-
thrombin complex concentrate) — a bridge be-
tween the normalization of the coagulation profile 
and the establishment of hemostasis, according 
to in vitro and preclinical data4,5 — in addition to 
idarucizumab. It can be reasonably argued that 
the establishment of effective hemostasis with 
blood-component and idarucizumab therapy out-
weighs the risk of thrombotic adverse events 
among patients with serious hemorrhaging. The 
effectiveness and need for further blood-compo-
nent and idarucizumab therapy may be assessed 
by serial clinical assessments and a serial profile 
of clotting times.
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To the Editor: In 2015, an interim analysis in-
volving 51 patients with acute bleeding who had 
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received idarucizumab for dabigatran reversal 
was published in the Journal.1 That article report-
ed a median time to the cessation of bleeding of 
11.4 hours among 35 of 51 patients (69%). At a 
2016 American Heart Association conference, 
data from 298 patients with acute bleeding were 
presented. The median time to the cessation of 
bleeding was reported in 158 patients (53%) as 
3.5 hours among 97 patients with gastrointesti-
nal bleeding and as 4.5 hours among 61 patients 
with nongastrointestinal and nonintracranial 
bleeding.2 Finally, in the full cohort analysis in-
volving 503 patients, of the 301 patients with 
acute bleeding, the median time to the cessation 
of bleeding is reported as 2.5 hours but was ana-
lyzed in only 134 patients (45%).
We are concerned that selective reporting bias 
influenced the reporting of this important sec-
ondary clinical outcome, because each subsequent 
analysis reduced the fraction of the cohort in-
cluded in this calculation (from 69% to 53% to 
45%) while increasing the apparent clinical effi-
cacy. We ask the authors to provide substantially 
more robust reporting of these data for the full 
cohort to better illuminate these evolving results.
Ryan P. Radecki, M.D.
University of Texas Health Science Center at Houston 
Houston, TX
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To the Editor: Pollack et al. report the antici-
pated final results of the RE-VERSE AD study 
regarding the use of idarucizumab to reverse the 
effects of dabigatran in patients who have life-
threatening hemorrhage or who are undergoing 
emergency surgery. However, the authors do not 
report the correlation between the activated par-
tial-thromboplastin time (aPTT) and the diluted 
thrombin time, the ecarin clotting time, or dabi-
gatran concentration. There is some evidence,1,2 
and some degree of consensus,3 that the aPTT 
(the only measurement available in emergency 
situations in most centers) is too insensitive to es-
timate dabigatran concentration, but little of the 
evidence has been gathered in the context of 
urgent reversal and not in a prespecified peak–
trough fashion. Therefore, an analysis of this 
correlation in the more than 500 patients who 
were included in the RE-VERSE AD study would 
be valuable. Given that urgent reversal is a rare 
need, this information is not likely to be obtained 
otherwise. Were the aPTT results not reported or 
analyzed because of the already available evi-
dence that aPTT should not be used? Would the 
authors provide sensitivity and specificity and 
predictive values for aPTT to detect therapeutic 
dabigatran concentrations?
Marc Sorigue, M.D.
Institut Català d’Oncologia 
Badalona, Spain 
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The authors reply: Idarucizumab is licensed for 
dabigatran reversal in patients who have serious 
bleeding or are undergoing urgent surgery. Yip 
and Deng speculate that in addition to idarucizu-
mab, prohemostatic agents such as prothrombin 
complex concentrate or recombinant activated 
factor VII should be administered to hasten hemo-
stasis in dabigatran-treated patients with severe 
hemorrhage. Few of the patients who were en-
rolled in the RE-VERSE AD study received pro-
hemostatic agents in addition to idarucizumab, 
so the efficacy and safety of such therapy cannot 
be assessed.1 However, prohemostatic agents are 
unlikely to be of benefit unless there is associat-
ed coagulopathy, because idarucizumab reverses 
the anticoagulant effects of dabigatran within 
minutes. Furthermore, prohemostatic agents may 
increase the risk of thrombosis.
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Radecki and DeLoughery are concerned about 
the divergence in the median times to the cessa-
tion of bleeding that were reported in the interim 
and final analyses of the data from the RE-VERSE 
AD study. For patients with serious bleeding, the 
protocol mandated the assessment of the time to 
the cessation of bleeding up to 24 hours after the 
administration of the first vial of idarucizumab.1 
The longer time that was reported in the interim 
analyses2,3 reflects the inclusion of patients with 
recorded times exceeding 24 hours and patients 
with intracranial hemorrhage, many of whom 
did not undergo repeat brain imaging until sev-
eral days after admission. To adhere to the per-
protocol definition, these patients were excluded 
in the final analysis, which explains the shorter 
times to the cessation of bleeding. We agree that 
their exclusion limits the generalizability of the 
findings to this subgroup. Therefore, postmarket-
ing data are needed to better assess the effect 
of idarucizumab on the time to the cessation of 
bleeding in these patients.4
Sorigue correctly points out that the diluted 
thrombin time or ecarin clotting time is not avail-
able in many hospitals, and he requests informa-
tion on the correlation between the aPTT and 
these tests. This information is provided in Fig-
ure 1D of our article and in Figure S2 in the 
Supplementary Appendix (available with the full 
text of our article at NEJM.org), which show that 
there is good correlation between the aPTT as 
measured in the central laboratory and the more 
specialized tests. Therefore, these data provide 
preliminary evidence that the aPTT can also be 
used to monitor dabigatran reversal, provided 
that the test is performed with a reagent that is 
sensitive to the anticoagulant effects of dabiga-
tran. In the RE-VERSE AD study, the central labo-
ratory used the CK-Prest reagent (Diagnostica 
Stago). It is important to point out, however, that 
coagulation testing before the administration of 
idarucizumab is not essential in patients who 
have life-threatening bleeding or in whom urgent 
surgery is indicated.
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IgG Endopeptidase in Highly Sensitized Patients Undergoing 
Transplantation
To the Editor: The study conducted by Jordan 
et al. (Aug. 3 issue)1 included a low-risk popula-
tion (2 patients did not have donor-specific anti-
bodies) and pretreatment class I donor-specific 
antibody levels (the major risk factor for anti-
body-mediated rejection) were modest (mean [±SD] 
fluorescence intensity, 5660±2364), yet a high 
rate of rejection occurred (10 of 22 patients [45%] 
with donor-specific antibodies). These data raise 
serious concerns for higher-risk patients.
A high rate of delayed graft function (77% of 
patients) occurred in the U.S. cohort, despite a 
short cold ischemia time (mean, 19.9±5.2 hours). 
Did kidney biopsies that were performed in pa-
tients with delayed graft function reveal endothe-
lial or renal tubular injury? Since donor-specific 
antibodies induce pathogenic signaling proper-
ties in endothelium,2 it is important to determine 
whether F(ab′)2 donor-specific antibody frag-
ments retain signaling properties, particularly if 
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